These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

916 related articles for article (PubMed ID: 17482113)

  • 1. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes.
    Slosar PJ; Josey R; Reynolds J
    Spine J; 2007; 7(3):301-7. PubMed ID: 17482113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft.
    Dimar JR; Glassman SD; Burkus KJ; Carreon LY
    Spine (Phila Pa 1976); 2006 Oct; 31(22):2534-9; discussion 2540. PubMed ID: 17047540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers.
    Glassman SD; Dimar JR; Burkus K; Hardacker JW; Pryor PW; Boden SD; Carreon LY
    Spine (Phila Pa 1976); 2007 Jul; 32(15):1693-8. PubMed ID: 17621221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.
    Crawford CH; Carreon LY; McGinnis MD; Campbell MJ; Glassman SD
    Spine (Phila Pa 1976); 2009 Jun; 34(13):1390-4. PubMed ID: 19440166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long adult spinal deformity fusion to the sacrum using rhBMP-2 versus autogenous iliac crest bone graft.
    Maeda T; Buchowski JM; Kim YJ; Mishiro T; Bridwell KH
    Spine (Phila Pa 1976); 2009 Sep; 34(20):2205-12. PubMed ID: 19752707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study.
    Vaccaro AR; Whang PG; Patel T; Phillips FM; Anderson DG; Albert TJ; Hilibrand AS; Brower RS; Kurd MF; Appannagari A; Patel M; Fischgrund JS
    Spine J; 2008; 8(3):457-65. PubMed ID: 17588821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posterolateral lumbar spine fusion with INFUSE bone graft.
    Glassman SD; Carreon L; Djurasovic M; Campbell MJ; Puno RM; Johnson JR; Dimar JR
    Spine J; 2007; 7(1):44-9. PubMed ID: 17197332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion.
    Buttermann GR
    Spine J; 2008; 8(3):426-35. PubMed ID: 17977799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
    Haid RW; Branch CL; Alexander JT; Burkus JK
    Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions.
    Vaidya R; Sethi A; Bartol S; Jacobson M; Coe C; Craig JG
    J Spinal Disord Tech; 2008 Dec; 21(8):557-62. PubMed ID: 19057248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cantilever TLIF with structural allograft and RhBMP2 for correction and maintenance of segmental sagittal lordosis: long-term clinical, radiographic, and functional outcome.
    Anand N; Hamilton JF; Perri B; Miraliakbar H; Goldstein T
    Spine (Phila Pa 1976); 2006 Sep; 31(20):E748-53. PubMed ID: 16985443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of bone morphogenetic protein-2 in mature adults: posterolateral non-instrument-assisted lumbar decompression and fusion.
    Hamilton DK; Jones-Quaidoo SM; Sansur C; Shaffrey CI; Oskouian R; Jane JA
    Surg Neurol; 2008 May; 69(5):457-61; discussion 461-2. PubMed ID: 18207557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complications associated with single-level transforaminal lumbar interbody fusion.
    Rihn JA; Patel R; Makda J; Hong J; Anderson DG; Vaccaro AR; Hilibrand AS; Albert TJ
    Spine J; 2009 Aug; 9(8):623-9. PubMed ID: 19482519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.
    Adams CL; Ogden K; Robertson IK; Broadhurst S; Edis D
    Spine (Phila Pa 1976); 2014 Jan; 39(2):164-71. PubMed ID: 24153173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion.
    Glassman SD; Carreon LY; Campbell MJ; Johnson JR; Puno RM; Djurasovic M; Dimar JR
    Spine J; 2008; 8(3):443-8. PubMed ID: 17526436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2: a prospective study of complications.
    Malham GM; Parker RM; Ellis NJ; Blecher CM; Chow FY; Claydon MH
    J Neurosurg Spine; 2014 Dec; 21(6):851-60. PubMed ID: 25279655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
    Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
    Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2.
    Pradhan BB; Bae HW; Dawson EG; Patel VV; Delamarter RB
    Spine (Phila Pa 1976); 2006 May; 31(10):E277-84. PubMed ID: 16648733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rhBMP-2 enhancement of posterolateral spinal fusion in a rabbit model in the presence of concurrently administered doxorubicin.
    Singh K; Smucker JD; Ugbo JL; Tortolani PJ; Tsai L; Fei Q; Kuh S; Rumi M; Heller JG; Boden SD; Yoon ST
    Spine J; 2007; 7(3):326-31. PubMed ID: 17482116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion.
    Akamaru T; Suh D; Boden SD; Kim HS; Minamide A; Louis-Ugbo J
    Spine (Phila Pa 1976); 2003 Mar; 28(5):429-34. PubMed ID: 12616152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.